Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or
There is provided a composition or kit of parts comprising: one or more compounds capable of treating and/or preventing an inflammatory disease of the gastrointestinal tract: and an iron hydroxypyrone, for increasing the level of iron in a patient's bloodstream and/or treating and/or preventing anaemia such as iron deficiency anaemia. A composition comprising iron hydroxypyrone is also provided for administration to a subject: having or at risk of having achlorhydria; wherein the gastric pH of the subject is equal to or greater than about 4; or wherein the subject has an inflammatory disease of the gastrointestinal tract.
1. A method for increasing the level of iron in a subject's bloodstream and/or for preventing and/or treating anaemia in the subject, wherein the method consists of the steps of administering a composition comprising an iron hydroxypyrone to the subject, and maintaining the gastric pH of the subject greater that 4 during said method.
2. The method according to claim 1 , wherein the composition is administered by oral administration or, wherein the method is for the absorption of iron.
3. The method according to claim 1 , wherein the anaemia is iron deficiency anaemia.
4. The method according to claim 1 , wherein the gastric pH is greater than 5 or 6.
5. The method according to claim 4 , wherein the gastric pH is about 6.5 or above.
6. The method according to claim 1 , wherein the iron hydroxypyrone comprises a ferric complex with hydroxypyrone, or a mixture of a ferrous or ferric salt and a hydroxypyrone and wherein the hydroxypyrone comprises a 3-hydroxy-4-pyrone or a 3-hydroxy-4-pyrone in which one or more of the hydrogen atoms attached to the ring carbon atoms are replaced by an aliphatic hydrocarbon group of 1 to 6 carbon atoms.
7. The method according to claim 1 , wherein the iron hydroxypyrone comprises ferric trimaltol or an iron (II) or iron (III) carboxylate and maltol.
8. The method according to claim 1 , wherein the composition is administered to a human or animal.
9. A method for increasing the level of iron in a subject's bloodstream and/or for preventing and/or treating anaemia in the subject, wherein the method consists of the step of administering a composition comprising an iron hydroxypyrone to the subject having, or at risk of having, achlorhydria, and wherein the iron hydroxypyrone is administered in the absence of a gastrointestinal pH lowering agent.
10. The method according to claim 9 , wherein the anaemia is iron deficiency anaemia.
11. The method according to claim 9 , wherein the achlorhydria is associated with an inflammatory disease of the gastrointestinal tract or wherein the achlorhydria is associated with atrophic gastritis or a gastrointestinal infection, such as caused by Helicobacter pylori.
12. A method for increasing the level of iron in a subject's bloodstream and/or for preventing and/or treating anaemia in the subject, wherein the method consists of the step of administering a composition comprising an iron hydroxypyrone to a subject, and maintaining the gastric pH of the subject greater than 4 during the method, wherein the subject has an inflammatory disease of the gastrointestinal tract.
13. The method according to claim 12 , wherein the anaemia is iron deficiency anaemia.
14. The method of claim 12 , wherein the gastric pH of the subject is greater than 5 or 6.
15. The method according to claim 14 , wherein the gastric pH is about 6.5 or above.
16. The method according to claim 6 , wherein the ferrous salt is an iron (II) carboxylate.
17. The method according to claim 6 , wherein the iron (II) carboxylate is selected from iron (II) gluconate, iron (II) succinate and iron (II) fumarate.
18. The method according to claim 1 , claim 9 or claim 12 , wherein the pH of the environment where iron is absorbed is greater than 4.
19. A method for increasing the level of iron in a subject's bloodstream and/or preventing and/or treating anaemia in the subject, wherein the method comprises the step of administering a composition comprising ferric trimaltol to the subject, wherein the gastric pH of the subject is greater than 6 and wherein iron is absorbed in the subject from the ferric trimaltol.
20. The method according to claim 1 , claim 9 or claim 12 , wherein the iron hydroxypyrone is administered with a pharmaceutically acceptable diluent or carrier.